Dec 30, 2025 • PR Newswire
SOMEWHAT-BEARISH
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.
DOMA Perpetual Capital Management LLC, owning approximately 6.83% of Pacira BioSciences, Inc. (NASDAQ: PCRX), plans to nominate three independent director candidates at the 2026 annual meeting. DOMA urges Pacira's Board to pursue an immediate sale of the company, citing exorbitant executive compensation and questioning the Board's fiduciary oversight. The firm asserts that the Board should conduct a formal sales process for the business.
Dec 30, 2025 • MarketBeat
NEUTRAL
Pacira BioSciences, Inc. $PCRX Shares Sold by Simplify Asset Management Inc.
Simplify Asset Management Inc. reduced its holdings in Pacira BioSciences, Inc. by 62.8% in Q3, selling 75,897 shares and retaining 44,946 shares valued at $1.16 million. Insiders also sold 32,920 shares in the last quarter, bringing insider ownership to 6.4%. Despite beating EPS estimates, Pacira slightly missed revenue expectations but saw a 6.5% year-over-year revenue increase.
Dec 28, 2025 • KXAN Austin
NEUTRAL
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Pacira BioSciences, Inc. (NASDAQ:PCRX) for corporate wrongdoing. The firm encourages investors who purchased Pacira securities before August 2, 2023, and still hold them, to contact them for more information. The investigation aims to determine if there were any unlawful acts by the company's officers or directors.
Dec 27, 2025 • MarketBeat
NEUTRAL
75,598 Shares in Pacira BioSciences, Inc. $PCRX Purchased by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC acquired 75,598 shares of Pacira BioSciences (NASDAQ:PCRX) in Q3, increasing institutional ownership to approximately 99.73%. Pacira reported Q3 EPS of $0.70, beating estimates, and revenue of $179.52M, with a 6.5% year-over-year growth. Analysts currently rate the stock as "Hold" with an average price target of $28.20.
Dec 26, 2025 • FOX40 News
BEARISH
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Pacira BioSciences, Inc. (NASDAQ:PCRX). The firm is encouraging investors who purchased Pacira securities before August 2, 2023, and continue to hold them, to come forward and assist with the investigation. The firm specializes in securities fraud class actions and shareholder derivative suits and represents investors on a contingency fee basis.
Dec 26, 2025 • WJBF
NEUTRAL
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Pacira BioSciences, Inc. (NASDAQ: PCRX) and certain officers/directors. The firm is encouraging investors who purchased Pacira securities before August 2, 2023, and continue to hold them, to come forward and learn more about the investigation. They represent investors on a contingency fee basis in class actions and shareholder derivative suits.